Form 4: Director Sue-Jean Lin Receives ARQT Equity Grant

Arcutis Biotherapeutics director Sue-Jean Lin was granted 5,778 restricted stock units and 16,667 stock options.

Summary

• Director Sue-Jean Lin received an equity grant of 5,778 Restricted Stock Units (RSUs) on June 5, 2026.
• The director was also granted 16,667 stock options with an exercise price of $21.23.
• Both the RSUs and options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.
• The reporting person now holds 32,513 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.
• The grant is standard compensation for non-employee director service following the annual meeting.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Future share price performance is required for the stock options to provide value to the director.
• Continued service is required for the vesting of both RSUs and options.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of director compensation.

Management Comments

• The grants are provided in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with shareholder interests.

Comparison to Industry Standards

• The grant structure is consistent with typical compensation packages for directors at mid-cap biopharmaceutical companies.
• Vesting schedules tied to annual meetings are standard practice for board members.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs and options on the earlier of June 5, 2027, or the next annual meeting.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Trading, Director Compensation, Equity Grant